Login to Your Account



GSK could find itself blacklisted under China’s new anti-bribery rules

By Shannon Ellis
Staff Writer

Wednesday, January 8, 2014

SHANGHAI – China has issued two legal announcements in its bid to root out corruption in the pharmaceutical industry. They focus on both the demand and supply side of corruption in China, targeting pharma companies that pay bribes and the doctors who accept them.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription